Pharmacological and clinical profile of recently approved second-generation antipsychotics: Implications for treatment of schizophrenia in older patients

Drugs and Aging

Volumn 29, Issue 10, 2012, Pages 783-791

  Rado, Jeffrey ^a   Janicak, Philip G ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; BENZODIAZEPINE; CHLORPROMAZINE; CLOZAPINE; CREATININE; HALOPERIDOL; ILOPERIDONE; LURASIDONE; OLANZAPINE; OROSOMUCOID; PALIPERIDONE; PLACEBO; PROLACTIN; QUETIAPINE; RISPERIDONE;

AGED; AGITATION; AKATHISIA; ANTICHOLINERGIC EFFECT; AREA UNDER THE CURVE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE DEFECT; COMORBIDITY; COMPARATIVE EFFECTIVENESS; CREATININE CLEARANCE; DIZZINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELDERLY CARE; EXECUTIVE FUNCTION; EXTRAPYRAMIDAL SYMPTOM; FIRST PASS EFFECT; GENETIC POLYMORPHISM; HALLUCINATION; HUMAN; HYPERPROLACTINEMIA; HYPERTENSION; LIVER DISEASE; MAXIMUM PLASMA CONCENTRATION; MEDICATION THERAPY MANAGEMENT; NEGATIVE SYNDROME; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PARKINSONISM; PERSECUTORY DELUSION; PLASMA PROTEIN BINDING; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; STANDING; SYMPTOM; TACHYCARDIA; TARDIVE DYSKINESIA; THOUGHT DISORDER; TONGUE HYPESTHESIA; TREATMENT DURATION; WEIGHT GAIN;

AGED; ANTIPSYCHOTIC AGENTS; DRUG APPROVAL; HUMANS; SCHIZOPHRENIA;

EID: 84874582243     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-012-0009-0     Document Type: Review

References (81)

1. Rado J, Janicak PG. Schizophrenia. In: Rakel RE, Bope ET, editors. Conn's current therapy 2009. Philadelphia: Saunders Elsevier; 2009.
2. Rabins PV, Black B, German P, et al. The prevalence of psychiatric disorders in elderly residents of public housing. J Gerontol A Biol Sci Med Sci. 1996;51(6):M319-24.
3. Girard C, Simard M. Clinical characterization of late- and very late-onset first psychotic episode in psychiatric inpatients. Am J Geriatr Psychiatr. 2008;16:478-87.
4. Cohen CI. Studies of the outcome of schizophrenia in later life. Psychiatr Serv. 1995;46:877-9.
5. Bartels SJ, Muser KT, Miles KM. Functional impairments in elderly patients with schizophrenia and major affective disorders living in the community: social skills, living skills and behaviour problems. Behav Ther. 1997;28:43-63. (Pubitemid 27319034)
6. Klapow J, Evans J, Patterson TL, et al. Direct assessment of functional status in older patients with schizophrenia. Am J Psychiatr. 1997;154:1022-4. (Pubitemid 27274550)
7. Patterson TL, Klapow JC, Eastham JH, et al. Correlates of functional status in older outpatients. Psychiatr Res. 1998;80:41-52. (Pubitemid 28370838)
8. Gupta S, Steinmeyer CH, Lockwood K, et al. Comparison of older patients with bipolar disorder and schizophrenia/schizoaffective disorders. Am J Geriatr Psychiatr. 2007;15:627-33.
9. Berry K, Barrowclough C. The needs of older adults with schizophrenia: implication for psychological interventions. Clin Psychol Rev. 2009;29:68-76.
10. Cohen CI. Age-related correlations in patient symptom management strategies in schizophrenia: an exploratory study. Int J Geriatr Psychiatr. 1993;8:211-3. (Pubitemid 23122993)
11. Salano N, Krauss Whitbourne S. Coping with schizophrenia: patterns in later adulthood. Int J Aging Hum Dev. 2001;53:1-10. (Pubitemid 32976623)
12. Howard R, Rabins PV, Seeman MV, Jeste DV, The International Late-Onset Schizophrenia Group. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. Am J Psychiatr. 2000;157(2):172-8. (Pubitemid 30080894)
13. Harvey PD, Friedman JI. Cognitive functioning in late-life schizophrenia. In: Cohen CI, editor. Schizophrenia into later life. Arlington, American Psychiatric Publishing; 1999.
14. Kurtz MM. Neurocognitive impairment across the lifespan in schizophrenia: an update. Schizophr Res. 2005;74:15-26. (Pubitemid 40203180)
15. Jeste DV, Symonds LL, Harris MJ, et al. Non-dementia non-praecox dementia praecox? Late-onset schizophrenia. Am J Geriatr Psychiatr. 1997;5:302-17. (Pubitemid 27483910)
16. Cuffel BJ, Jeste DV, Halpain M, et al. Treatment costs and use of community mental health services for schizophrenia by age-cohorts. Am J Psychiatr. 1996;153:870-6. (Pubitemid 26225460)
17. Zisook S, McAdams LA, Kuck J, et al. Depressive symptoms in schizophrenia. Am J Psychiatr. 1999;156:1736-43. (Pubitemid 29517566)
18. Jin H, Zisook S, Palmer B, et al. Association of depressive symptoms with worse functioning in schizophrenia: a study of older outpatients. J Clin Psychiatr. 2001;62:797-803. (Pubitemid 33104666)
19. Meeks S, Woodruff-Borden J. Anxiety: comorbidity and impact in severe mental illness. J Clin Geropsychol. 1996;2:141-52.
20. Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophr Res. 2000;45:21-8.
21. Howanitz E, Pardo M, Smelson DA, Engelhart C, Eisenstein N, Losonczy MF. The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. J Clin Psychiatr. 1999;60(1):41-4. (Pubitemid 29069885)
22. Kennedy JS, Jeste D, Kaiser CJ. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial. Int J Geriatr Psychiatr. 2003;18:1013-20. (Pubitemid 37479374)
23. Jeste DV, Barak Y, Madhusoodanan S, Grossman F, Gharabawi G. International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am J Geriatr Psychiatr. 2003;11:638-47. (Pubitemid 37392328)
24. Mazeh D, Paleacu D, Barak Y. Quetiapine for elderly non-responsive schizophrenia patients. Psychiatr Res. 2008;157:265-7. (Pubitemid 350166561)
25. Wlodzimiewrz CK, Marcus RN, Tobeyns A, Nyilas M, McQuade RD. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology. 2006;189:259-66. (Pubitemid 44691547)
26. Takeuchi H, Suzuki T, Uchida H, et al. A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia. J Clin Psychopharmacol. 2008;28:540-3.
27. Madhusoodan S, Brenner R, Gupta S, Reddy H, Bogunovic O. Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies. CNS Spectr. 2004;9(11):862-7. (Pubitemid 39602941)
28. Shastri M, Alla L, Sabaratnam M. Aripiprazole use in individuals with intellectual disability and psychotic or behavioural disorders: a case series. J Psychopharmacol. 2006;20(6):863-7. (Pubitemid 44622753)
29. Ponde MP, Novaes CM. Aripiprazole worsening positive symptoms and meantime reducing negative symptoms in a patient with paranoid schizophrenia. Rev Bras Psiquiatr. 2007;28(1):86-95.
30. Carney C, Jones L, Woolson RF. Medical comorbidity in women and men with schizophrenia. J Gen Intern Med. 2006;21:1133-7. (Pubitemid 44506864)
31. Janicak PG, Marder S, Pavuluri M. Principles and practice of psychopharmacotherapy. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2011. p. 633-61.
32. Tzimos A, Samokhvalov V, Kramer M, et al. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with long-term open-label extension. Am J Geriatr Psychiatr. 2008;16(1):31-43.
33. INVEGA package insert. Prescribing information for paliperidone extended-release [online]. 2007. http://www.janssen.com. Accessed June 2007.
34. ®), and advanced oral delivery form. Curr Med Res Opin. 2005;22:1879-92. (Pubitemid 44663390)
35. Gram S, Fitlon A. Risperidone: a review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs. 1994;48(2):253-73.
36. Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389-409. (Pubitemid 43763739)
37. Karlsson P, Dencker E, Nyberg S, et al. Pharmacokinetics and dopamine D(2) and serotonin 5-HT(2A) receptor occupancy of paliperidone in healthy subjects [abstract no. P.1.053]. Eyr Neuropsychopharmacol. 2005;15(Suppl. 3):386. Plus poster presented at the 18th European College of Neuropsychopharmacology Congress; 2005 Oct 22-26; Amsterdam.
38. Leysen JE, Janssen PM, Megens AA, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatr. 1994;55(Suppl. 5):5-12. (Pubitemid 24179363)
39. Cleton A, Rossenu S, Vermeulen A, et al. A pharmacokinetic model to document the interconversion between paliperidone's enantiomers [abstract no. PII-72]. Clin Pharmacol Ther. 2006;79(2):55.
40. Yang LPH, Plosker GL. Paliperidone extended release. CNS Drugs. 2007;21(5):1172-7047. (Pubitemid 46698504)
41. Rossenu S, Cleton A, Talluri K, et al. Evaluation of the pharmacokinetics of an extended-release formulation of paliperidone with an immediate-release formulation of risperidone. Clin Pharm Ther. 2007;81(Suppl. 1):S62.
42. Mannens G, Meuldermans W, Snoeck E, Heykants J. Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology. 1994;114:566-72. (Pubitemid 24152136)
43. Vermeir M, Boom S, Naessens I, et al. Absorption, metabolism and excretion of a single oral dose of 14C-paliperidone 1 mg in healthy subjects. Eur Neuropsychopharmacol. 2005;30:S191-2.
44. Thyssen A, Cleton A, Talluri K, Leempoels J, Janssens L, Boom S, Eerdekens M. No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects. Hum Psychopharmacol. 2009;24(7):532-9.
45. Meltzer H, Kramer M, Gassmann-Mayer C, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week placebo controlled studies. Int J Neuropsychopharmacol. 2006;9:S225.
46. Janicak PG, Winans EA, Paliperidone ER. A review of the clinical trial data. Neuropsychiatr Dis Treat. 2007;3(6):1-15.
47. Hough DW, Natarajan J, Vandebosh A, et al. Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2011;26(1):25-34.
48. Knegtering R, Baselmans P, Castelein S, et al. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatr. 2005;2005(162):1010-2. (Pubitemid 40676220)
49. Boom S, Thyssen A, Crauwels H, et al. The influence of hepatic impairment on the pharmacokinetics of paliperidone. Int J Clin Pharmacol Ther. 2009;47(10):606-16.
50. Thyssen A, Cleton A, Osselae NV. Effects of renal impairment on the pharmacokinetic profile of paliperidone extended-release tablets. Clin Pharm Ther. 2007;81(Suppl. 1):S63.
51. Samtani MN, Gopal S, Gassmann-Mayer C, Alphs L, Palumbo JM. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modeling and clinical trial data. CNS Drugs. 2011;25(10):829-45.
52. Samtani M, Sliwa JK, Haskins JT, et al. Initiation of dosing and deltoid intramuscular paliperidone palmitate in schizophrenia: pharmacokinetic rationale based on modeling and simulation. J Pharm Pract. 2009;22:216-7.
53. Hough D, Lindenmayer JP, Gopal S, et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatr. 2009;33(6):1022-31.
54. Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet. 2009;48(9):585-600.
55. Rado J, Janicak PG. A novel treatment option for schizophrenia. Psychopharm Rev. 2010;45(1):1-8.
56. Potkin SG, Litman RE, Torres R, et al. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol. 2008;28:S4-11. (Pubitemid 351397671)
57. Cutler AJ, Kalali AH, Weiden PJ, et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008;28(2 Suppl. 1):S20-8. (Pubitemid 351397673)
58. Weiden PJ, Cutler AJ, Polymeropoulos MH, et al. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol. 2008;28(2 Suppl. 1):S12-9. (Pubitemid 351397672)
59. Ichikawa J, Li Z, Dai J, et al. Atypical antipsychotic drugs, quetiapine, iloperidone and melperidone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res. 2002;956:349-57. (Pubitemid 35351402)
60. Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology. 2001;25:904-14. (Pubitemid 34031895)
61. Kalkman HO, Feuerbach D, Lotscher E. Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha 2C, 5-HT6, and 5-HT1A receptors. Life Sci. 2003;73(9):1151-9. (Pubitemid 36724916)
62. ® (iloperidone) prescribing information. http://www.pharma.us.novartis.com/product/pi/pdf/fanapt.pdf. Accessed 16 Jan 2012.
63. Subramanian N, Kalkman HO. Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone. Prog Neuropsychopharmacol Biol Psychiatr. 2002;26:553-60. (Pubitemid 34252950)
64. Volpi S, Potkin SG, Malhotra AK, et al. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J Clin Psychiatr. 2009;70(6):801-9.
65. Volpi S, Heaton C, Mack K, et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment in schizophrenia. Mol Psychiatr. 2009;14(11):1024-31.
66. Dubovsky SL, Frobose C, Phiri P, et al. Short-term safety and pharmacokinetic profile of asenapine in older patients with psychosis. Int J Geriatr Psychiatr. 2012;27(5):472-82.
67. Hulskotte E, Spaans E, Timmer C. Effects of water intake and smoking on the absorption of sublingually administered asenapine [abstract no. PIII-57]. Clin Pharmacol Ther. 2009;85(Suppl. 1):S20-8.
68. Janicak PG, Rado JT. Asenapine. a review of the data. Psychopharm Rev. 2009;44(12):89-96.
69. Shoemaker J, Naber D, Vrijland P, Panagides J, Emsley R. Long-term assessment of asenapine versus olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry. 2010;43:138-46.
70. Chapel S, Hutmacher MM, Haig G, et al. Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation. J Clin Pharmacol. 2009;49:1297-308.
71. Shahid M, Walker GB, Zorn SN, et al. Asenapine: a novel psychopharmacological agent with a unique human receptor signature. J Psychopharmacol. 2009;23(1):65-73.
72. ABILIFY® (aripiprazole) prescribing information. http://www.abilify. com/pdf/pi.aspx?tc=89340&utm-source=google&utm-medium= organic-search&utm-term=aripiprazole+prescribing+information&q= aripiprazole+prescribing+information&hl=en&source=hp&gs-sm= s&gs-upl=1375l1375l0l1828l1l1l0l0l0l0l0l0ll0l0&oq= aripiprazole+prescribing+information&aq=f&aqi=g1&aql=1. Accessed 25 Oct 2011.
73. Peeters P, Bockbrader H, Spaans E, et al. Asenapine pharmacokinetics in hepatic and renal impairment. Clin Pharmacokinet. 2011;50(7):471-81.
74. Fayad SM, Tandon R. Lurasidone: the most recent addition to our antipsychotic armentarium: a review of the data. Psychopharm Rev. 2011;46(6):41-8.
75. Latuda prescribing information. http://www.latuda.com/aboutLatuda/taking- latuda.html. Accessed 25 Oct 2011.
76. Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs. 2009;18(11):1715-26.
77. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatr. 2009;70(6):829-36.
78. Harvey PD, Ogasa M, Cucchiaro J, et al. Performance and interview-based assessments of cognitive change in a randomized, double blind comparison of lurasidone vs. ziprasidone. Schizophrenia Res. 2011;127:188-94.
79. Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxy-tryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010;334:171-81.
80. Guay DR. Comment on the potential utility of the new atypical antipsychotic lurasidone in the geriatric population. Consult Pharm. 2011;26(8):579-82.
81. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Intl J Clin Pract. 2011;65(2):189-210.